No Abstract Novosom AG, of Halle, Germany, received U.S. Patent No...Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No...Samaritan Pharmaceuticals, of Las Vegas, received U.S. Patent No

The patent protects the company's rights to manufacture the Celution System in the U.S...EntreMed Inc., of Rockville, Md., received U.S. Patent No

Genta Inc., of Berkeley Heights, N.J., was issued U.S. Patent No...Idera Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent Nos...Jivan Biologics Inc., of Berkeley, Calif., was awarded U.S. Patent No

Bioheart Inc., of Sunrise, Fla., was awarded U.S. Patent No...Biosearch Technologies Inc., of Novato, Calif., received U.S. Patent No...Elixir Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent No

CombinatoRx Inc., of Cambridge, Mass., was granted U.S. Patent No...Geneart AG, of Regensburg, Germany, received U.S. Patent Nos...VisiGen Biotechnologies Inc., of Houston, received U.S. Patent No

Theratechnologies Inc., of Montreal, received U.S. Patent No...Vermillion Inc., of Fremont, Calif., received U.S. Patent No...Xencor Inc., of Monrovia, Calif., received U.S. Patent No

Morphotek Inc., of Exton, Pa., received U.S. Patent No...RE39,816 (a reissue of U.S. Patent No. 6,461,828, titled "Conjunctive Analysis of Biological Marker Expression For Predicting Cardiac Mortality.") It relates to the combined use of a cardiac marker of cell injury with a marker of organ adaptation for prognosis of chronic congestive heart failure...Proteologics Inc., of Rehovot, Israel, received U.S. Patent No

Avicena Group Inc., of Palo Alto, Calif., received U.S. Patent No...CellCyte Genetics Corp., of Kirkland, Wash., received U.S. Patent No

Nventa Biopharmaceuticals Corp., of San Diego, was issued U.S. Patent No...Penwest Pharmaceuticals Co., of Danbury, Conn., received U.S. Patent No...Protox Therapeutics Inc., of Vancouver, British Columbia, received U.S. Patent No

Javelin Pharmaceuticals Inc., of Cambridge, Mass., was granted U.S. Patent No...MorphoSys AG, of Martinsried, Germany, was granted U.S. Patent No...Urigen Pharmaceuticals Inc., of Burlingame, Calif., received U.S. Patent No

AntiCancer Inc., of San Diego, received U.S. Patent No...BioNanomatrix Inc., of Philadelphia, was issued U.S. Patent No...Helix BioPharma Corp., of Aurora, Ontario, received U.S. Patent No

Rosetta Genomics Ltd., of Rehovot, Israel, received U.S. Patent No...Senomyx Inc., of San Diego, was issued U.S. Patent No...Targeted Genetics Corp., of Seattle received U.S. Patent No

Chembio Diagnostic Inc., of New York, received U.S. Patent No...Chromatin Inc., of Chicago, was granted U.S. Patent Nos...Inc., of Bothell, Wash., received U.S. Patent No

VASTox plc, of Oxford, UK, was granted a patent relating to its drug discovery program in Duchenne's muscular dystrophy...Vaxiion Therapeutics Inc., of San Diego, was issued U.S. Patent No

Q Therapeutics Inc., of Salt Lake City, received U.S. Patent No...Targeted Genetics Corp., of Seattle, received U.S. Patent No

Nventa Biopharmaceuticals Corp., of San Diego, received U.S. Patent No...Oncolytics Biotech Inc., of Calgary, was granted U.S. Patent No...7,166,702, titled "Cytotoxic Conjugates Comprising a Chemokine Receptor Targeting Agent," and U.S. Patent No

Carrington Laboratories Inc., of Irving, Texas, said its subsidiary, DelSite Biotechnologies Inc., was granted U.S. Patent No...Cel-Sci Corp., of Vienna, Va., was issued U.S. Patent No...Chembio Diagnostics Inc., of Medford, N.Y., received U.S. Patent No

ARC Pharmaceuticals Inc., of Vancouver, British Columbia, and the University of British Columbia received U.S. Patent No...Argos Therapeutics, of Durham, N.C., received U.S. Patent NO...Avicena Group Inc., of Palo Alto, Calif., received U.S. Patent No

Lpath Inc., of San Diego, received U.S. Patent No...Nventa Biopharmaceuticals Corp., of San Diego, received U.S. Patent No...PolyMedix Inc., of Philadelphia, received U.S. Patent No